Corbus Pharmaceuticals Holdings (CRBP) Cash from Operations (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Cash from Operations of 15550000.0 for Q3 2025, down 11.53% year-over-year from 17577274.2 in Q3 2024, and up 6.32% quarter-over-quarter from 16599000.0 in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Cash from Operations (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Cash from Operations history runs 13 years deep, the most recent figure standing at 15550000.0 for Q3 2025.
- In Q3 2025, Cash from Operations fell 11.53% year-over-year to 15550000.0; the TTM figure through Sep 2025 stood at 59512000.0 (down 61.45% YoY), while the FY2024 annual figure was 41794000.0, down 15.77% from the prior year.
- Cash from Operations for Q3 2025 stood at 15550000.0, up from 16599000.0 in the prior quarter.
- The five-year high for Cash from Operations was 856954.0 in Q3 2021, with the low at 21809505.0 in Q1 2021.
- The 5-year median for Cash from Operations is 10615350.0 (2022), against an average of 11168006.95.
- The sharpest annual moves came in 2021 and 2022: Cash from Operations surged 103.14% in 2021, then sank 945.44% in 2022.
- Corbus Pharmaceuticals Holdings' Cash from Operations stood at 9702575.0 in 2021, then gained by 23.16% to 7454985.0 in 2022, then grew by 19.41% to 6008000.0 in 2023, then sank by 82.12% to 10942000.0 in 2024, then sank by 42.11% to 15550000.0 in 2025.
- Business Quant data shows CRBP's Cash from Operations at 15550000.0 in Q3 2025, 16599000.0 in Q2 2025, and 16421000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -15.55 Mn |
| Sep 30, 2025 | -15.55 Mn |
| Jun 30, 2025 | -16.60 Mn |
| Jun 30, 2025 | -16.60 Mn |
| Mar 31, 2025 | -16.42 Mn |
| Mar 31, 2025 | -16.42 Mn |
| Dec 31, 2024 | -10.94 Mn |
| Dec 31, 2024 | -10.94 Mn |
| Sep 30, 2024 | -13.94 Mn |
| Sep 30, 2024 | -13.94 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Jun 30, 2024 | -8.94 Mn |
| Mar 31, 2024 | -7.97 Mn |
| Mar 31, 2024 | -7.97 Mn |
| Dec 31, 2023 | -6.01 Mn |
| Dec 31, 2023 | -6.01 Mn |
| Sep 30, 2023 | -7.18 Mn |
| Sep 30, 2023 | -7.18 Mn |
| Jun 30, 2023 | -7.80 Mn |
| Jun 30, 2023 | -7.80 Mn |